AR102803A1 - Vacunas de reovirus aviar - Google Patents
Vacunas de reovirus aviarInfo
- Publication number
- AR102803A1 AR102803A1 ARP150100252A ARP150100252A AR102803A1 AR 102803 A1 AR102803 A1 AR 102803A1 AR P150100252 A ARP150100252 A AR P150100252A AR P150100252 A ARP150100252 A AR P150100252A AR 102803 A1 AR102803 A1 AR 102803A1
- Authority
- AR
- Argentina
- Prior art keywords
- sequence identity
- seq
- sequence
- identity
- avian reovirus
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 241000702263 Reovirus sp. Species 0.000 title 1
- 241001516406 Avian orthoreovirus Species 0.000 abstract 5
- 238000000034 method Methods 0.000 abstract 4
- 101710117545 C protein Proteins 0.000 abstract 2
- 101150027674 S1 gene Proteins 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 239000002773 nucleotide Substances 0.000 abstract 2
- 125000003729 nucleotide group Chemical group 0.000 abstract 2
- 238000003752 polymerase chain reaction Methods 0.000 abstract 2
- 206010003274 Arthritis viral Diseases 0.000 abstract 1
- 241000272496 Galliformes Species 0.000 abstract 1
- 208000004575 Infectious Arthritis Diseases 0.000 abstract 1
- 208000004760 Tenosynovitis Diseases 0.000 abstract 1
- 230000003321 amplification Effects 0.000 abstract 1
- 230000001900 immune effect Effects 0.000 abstract 1
- 238000003199 nucleic acid amplification method Methods 0.000 abstract 1
- 244000144977 poultry Species 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/15—Reoviridae, e.g. calf diarrhea virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
- C12N2720/12221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
- C12N2720/12222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
- C12N2720/12234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
- C12N2720/12261—Methods of inactivation or attenuation
- C12N2720/12264—Methods of inactivation or attenuation by serial passage
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/14—Reoviridae, e.g. rotavirus, bluetongue virus, Colorado tick fever virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
Abstract
Reivindicación 1: Un reovirus aviar aislado, en donde el reovirus aviar comprende: (a) una proteína sigma C que comprende una secuencia de aminoácidos con al menos aproximadamente 80% de identidad de secuencia, al menos aproximadamente 85% de identidad de secuencia, al menos aproximadamente 90% de identidad de secuencia, al menos aproximadamente 95% de identidad de secuencia, al menos aproximadamente 96% de identidad de secuencia, al menos aproximadamente 97% de identidad de secuencia, al menos aproximadamente 98% de identidad de secuencia o al menos aproximadamente 99% de identidad de secuencia con la SEQ ID Nº 2 y/o SEQ ID Nº 4; (b) un gen S1 que comprende una secuencia de nucleótidos con al menos aproximadamente 80% de identidad de secuencia, al menos aproximadamente 85% de identidad de secuencia, al menos aproximadamente 90% de identidad de secuencia, al menos aproximadamente 95% de identidad de secuencia, al menos aproximadamente 96% de identidad de secuencia, al menos aproximadamente 97% de identidad de secuencia, al menos aproximadamente 98% de identidad de secuencia o al menos aproximadamente 99% de identidad de secuencia con la SEQ ID Nº 1 y/o SEQ ID Nº 3; (c) una proteína sigma C que comprende una secuencia de aminoácidos con al menos aproximadamente 85% de identidad de secuencia, al menos aproximadamente 90% de identidad de secuencia, al menos aproximadamente 95% de identidad de secuencia, al menos aproximadamente 96% de identidad de secuencia, al menos aproximadamente 97% de identidad de secuencia, al menos aproximadamente 98% de identidad de secuencia o al menos aproximadamente 99% de identidad de secuencia con la SEQ ID Nº 6; o (d) un gen S1 que comprende una secuencia de nucleótidos con al menos aproximadamente 85% de identidad de secuencia, al menos aproximadamente 90% de identidad de secuencia, al menos aproximadamente 95% de identidad de secuencia, al menos aproximadamente 96% de identidad de secuencia, al menos aproximadamente 97% de identidad de secuencia, al menos aproximadamente 98% de identidad de secuencia o al menos aproximadamente 99% de identidad de secuencia con la SEQ ID Nº 5. Reivindicación 19: Una composición inmunológica para aumentar anticuerpos en aves de corral comprendiendo la composición un reovirus aviar de cualquiera de las reivindicaciones 1 a 16. Reivindicación 27: Un método para prevenir la artritis viral y/o tenosinovitis en un ave del orden Galliformes, comprendiendo el método administrar al ave un reovirus aviar aislado de cualquiera de las reivindicaciones 1 a 16 o una composición o vacuna de cualquiera de las reivindicaciones 17 a 21. Reivindicación 39: Un método para detectar un reovirus aviar en una muestra, comprendiendo el método producir un producto de amplificación de reacción en cadena de polimerasa (PCR) con al menos un cebador derivado de la SEQ ID Nº 1, SEQ ID Nº 3 o SEQ ID Nº 5.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461932995P | 2014-01-29 | 2014-01-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR102803A1 true AR102803A1 (es) | 2017-03-29 |
Family
ID=53757708
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150100252A AR102803A1 (es) | 2014-01-29 | 2015-01-29 | Vacunas de reovirus aviar |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US9968671B2 (es) |
| EP (1) | EP3099789A4 (es) |
| JP (1) | JP6682441B2 (es) |
| KR (2) | KR102340265B1 (es) |
| CN (1) | CN106232808A (es) |
| AR (1) | AR102803A1 (es) |
| BR (1) | BR112016017333A2 (es) |
| CL (2) | CL2016001906A1 (es) |
| MX (1) | MX2016009747A (es) |
| RU (2) | RU2724497C2 (es) |
| WO (1) | WO2015116778A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106232808A (zh) | 2014-01-29 | 2016-12-14 | 乔治亚大学研究基金公司 | 禽类呼肠孤病毒疫苗 |
| BR112022010687A2 (pt) * | 2019-12-02 | 2022-08-23 | Univ Georgia | Cepas de reovírus aviário atenuado 94826 c140 e 96139 c140 |
| CN110760485B (zh) * | 2019-12-09 | 2023-02-24 | 天津渤海农牧产业联合研究院有限公司 | 一株禽呼肠孤病毒毒株及应用 |
| CN114592088B (zh) * | 2022-02-16 | 2024-04-02 | 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） | 一种用于检测或区分禽呼肠孤病毒4种不同基因型的多重pcr试剂盒及其应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999024582A1 (en) * | 1997-11-07 | 1999-05-20 | Dalhousie University | Novel reovirus-derived proteins, nucleic acids encoding same, and uses therefor |
| ES2240005T3 (es) * | 1999-01-29 | 2005-10-16 | Akzo Nobel N.V. | Nueva clase antigenica de reovirus aviar. |
| US8178110B2 (en) * | 2006-10-25 | 2012-05-15 | University Of Georgia Research Foundation, Inc. | Reovirus compositions and methods of use |
| WO2009093251A2 (en) * | 2008-01-24 | 2009-07-30 | Gavish-Galilee Bio Applications Ltd | Reovirus vaccine based on sigma c protein sequence |
| CN106232808A (zh) | 2014-01-29 | 2016-12-14 | 乔治亚大学研究基金公司 | 禽类呼肠孤病毒疫苗 |
-
2015
- 2015-01-29 CN CN201580006607.3A patent/CN106232808A/zh active Pending
- 2015-01-29 KR KR1020217005251A patent/KR102340265B1/ko active IP Right Grant
- 2015-01-29 EP EP15743978.7A patent/EP3099789A4/en active Pending
- 2015-01-29 MX MX2016009747A patent/MX2016009747A/es unknown
- 2015-01-29 WO PCT/US2015/013449 patent/WO2015116778A1/en active Application Filing
- 2015-01-29 AR ARP150100252A patent/AR102803A1/es unknown
- 2015-01-29 RU RU2019137459A patent/RU2724497C2/ru active
- 2015-01-29 KR KR1020167020781A patent/KR20160113137A/ko active Application Filing
- 2015-01-29 JP JP2016548717A patent/JP6682441B2/ja active Active
- 2015-01-29 RU RU2016134909A patent/RU2708316C2/ru active
- 2015-01-29 BR BR112016017333A patent/BR112016017333A2/pt not_active Application Discontinuation
-
2016
- 2016-07-27 CL CL2016001906A patent/CL2016001906A1/es unknown
- 2016-07-29 US US15/223,623 patent/US9968671B2/en active Active
-
2018
- 2018-04-23 US US15/959,503 patent/US10588958B2/en active Active
-
2019
- 2019-11-14 US US16/683,479 patent/US11090377B2/en active Active
-
2021
- 2021-11-18 CL CL2021003044A patent/CL2021003044A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3099789A1 (en) | 2016-12-07 |
| KR20160113137A (ko) | 2016-09-28 |
| WO2015116778A1 (en) | 2015-08-06 |
| CN106232808A (zh) | 2016-12-14 |
| US10588958B2 (en) | 2020-03-17 |
| RU2724497C2 (ru) | 2020-06-23 |
| RU2019137459A3 (es) | 2020-04-27 |
| US20170028055A1 (en) | 2017-02-02 |
| KR102340265B1 (ko) | 2021-12-15 |
| US9968671B2 (en) | 2018-05-15 |
| RU2019137459A (ru) | 2019-12-20 |
| JP6682441B2 (ja) | 2020-04-15 |
| JP2017506503A (ja) | 2017-03-09 |
| KR20210022165A (ko) | 2021-03-02 |
| US20200069788A1 (en) | 2020-03-05 |
| US20180236061A1 (en) | 2018-08-23 |
| EP3099789A4 (en) | 2017-09-13 |
| CL2021003044A1 (es) | 2022-08-26 |
| RU2016134909A (ru) | 2018-03-02 |
| BR112016017333A2 (pt) | 2017-10-17 |
| MX2016009747A (es) | 2016-11-09 |
| US11090377B2 (en) | 2021-08-17 |
| RU2016134909A3 (es) | 2019-02-18 |
| RU2708316C2 (ru) | 2019-12-05 |
| CL2016001906A1 (es) | 2017-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018500855A1 (en) | Herpes simplex virus vaccine | |
| BR112018013930A2 (pt) | vírus oncolítico, vírus que expressa três genes heterólogos, composição farmacêutica, vírus para o uso, produto de fabricação, método de tratamento de câncer e uso do vírus | |
| BR112016019267A2 (pt) | métodos e composições para perfil de dna | |
| ES2721309T3 (es) | Composición para preparar tagatosa y método para preparar tagatosa a partir de fructosa | |
| AR105822A1 (es) | Análogos de insulina | |
| BR112018067536A2 (pt) | sistema de transpóson e métodos de uso | |
| AR102803A1 (es) | Vacunas de reovirus aviar | |
| AR087885A1 (es) | Enzimas utiles para la industria alimenticia | |
| MX2018014163A (es) | Composiciones de nucleotido marcados y metodos para el secuenciamiento de acido nucleico. | |
| CO2017001614A2 (es) | Vacuna en vector recombinante de adenovirus aviar serotipo 9 | |
| MX366836B (es) | Celulas aviares para la produccion mejorada de virus. | |
| WO2015150492A3 (en) | An isolated donor mhc-derived peptide and uses thereof | |
| RU2016152662A (ru) | Микроорганизм рода Escherichia, продуцирующий L-триптофан, и способ продуцирования L-триптофана с использованием данного микроорганизма | |
| AR083445A1 (es) | siARN CONTRA LA FIBROSIS | |
| BR112018003580A2 (pt) | molécula de ácido nucléico, método para apresentar um polipeptídeo alvo, proteína recombinante, partícula do tipo viral, composição farmacêutica, polipeptídeo, vetor, célula hospedeira e método para preparar a proteína recombinante | |
| CL2019000405A1 (es) | Vacunas virales. | |
| AR110626A1 (es) | Paramixovirus y sus usos | |
| BR112016015875A2 (pt) | Elementos intensificadores de cpmv | |
| CL2020002373A1 (es) | Composición de vacuna que comprende un péptido aislado de piojo de mar; uso de la vacuna para para prevenir o controlar una infestación de piojos de mar en un salmónido; vector; célula hospedadora (divisional de la solicitud no. 201900422). | |
| AR102762A1 (es) | Secuencia de oligonucleótidos para uso en ingeniería de rutas metabólicas | |
| WO2015106067A3 (en) | Lucigen yellow (lucy), a yellow fluorescent protein | |
| AR102333A1 (es) | Selectividad eficiente de proteínas recombinadas | |
| EP3546594A3 (en) | Multi-copy reference assay | |
| ES2671745T3 (es) | Detección de Neisseria gonorrhoeae | |
| AR109167A1 (es) | Aumento de la fertilidad en especies bovinas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |